COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2500 participants.

Also called NCT05873881

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05873881
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05873881. Randomized; double masking; primary purpose treatment. Start 2024-01-29 (actual); primary completion 2027-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease
Acronym
COLT-HF
Condition
Heart Failure
Intervention (Drug)
Colchicine 0.5 MG
Intervention (Drug)
Colchicine placebo
Intervention (Drug)
Thiamine Mononitrate 300 mg
Lead sponsor
Hamilton Health Sciences Corporation (class: other)
Collaborator
Population Health Research Institute (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)

Record details

Record id
cardio:ct-nct05873881
Content hash
6eeff744c9d8b32dcdf0e142ee3f1db7003a5b4899f9090c5f970b2bfc6af997